Ionis Pharmaceuticals Inc (NASDAQ: IONS) is -0.06% lower on its value in year-to-date trading and has touched a low of $33.15 and a high of $54.44 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The IONS stock was last observed hovering at around $33.46 in the last trading session, with the day’s gains setting it 1.48%.
Currently trading at $34.94, the stock is -1.95% and -4.07% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 1.89 million and changing 4.42% at the moment leaves the stock -15.63% off its SMA200. IONS registered -33.08% loss for a year compared to 6-month loss of -27.21%. The firm has a 50-day simple moving average (SMA 50) of $36.5164 and a 200-day simple moving average (SMA200) of $41.4603.
The stock witnessed a -8.68% gain in the last 1 month and extending the period to 3 months gives it a -7.93%, and is 0.37% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 3.89% over the week and 3.54% over the month.
Ionis Pharmaceuticals Inc (IONS) has around 927 employees, a market worth around $5.52B and $803.56M in sales. Profit margin for the company is -44.62%. Distance from 52-week low is 5.40% and -35.82% from its 52-week high. The company has generated returns on investments over the last 12 months (-13.78%).
with sales reaching $141.1M over the same period.The EPS is expected to shrink by -36.81% this year, but quarterly earnings will post -21.31% year-over-year. Quarterly sales are estimated to shrink -56.58% in year-over-year returns.
Ionis Pharmaceuticals Inc (IONS) Top Institutional Holders
516.0 institutions hold shares in Ionis Pharmaceuticals Inc (IONS), with institutional investors hold 103.90% of the company’s shares. The shares outstanding are 157.81M, and float is at 145.55M with Short Float at 7.49%. Institutions hold 103.11% of the Float.
The top institutional shareholder in the company is FMR LLC with over 21.89 million shares valued at $1.04 billion. The investor’s holdings represent 15.044% of the IONS Shares outstanding. As of 2024-06-30, the second largest holder is VANGUARD GROUP INC with 13.85 million shares valued at $659.89 million to account for 9.5135 of the shares outstanding. The other top investors are T. ROWE PRICE INVESTMENT MANAGEMENT, INC. which holds 12.64 million shares representing 8.6848% and valued at over $602.41 million, while BLACKROCK INC. holds 7.0916 of the shares totaling 10.32 million with a market value of $491.9 million.
Ionis Pharmaceuticals Inc (IONS) Insider Activity
The most recent transaction is an insider purchase by Hayden Michael R, the company’s Director. SEC filings show that Hayden Michael R bought 5,000 shares of the company’s common stock on Dec 23 ’24 at a price of $36.22 per share for a total of $0.18 million. Following the purchase, the insider now owns 35219.0 shares.
Ionis Pharmaceuticals Inc disclosed in a document filed with the SEC on Nov 12 ’24 that Swayze Eric (EVP Research) sold a total of 1,194 shares of the company’s common stock. The trade occurred on Nov 12 ’24 and was made at $37.92 per share for $45278.0. Following the transaction, the insider now directly holds 33713.0 shares of the IONS stock.
Still, SEC filings show that on Nov 12 ’24, Monia Brett P (Chief Executive Officer) disposed off 6,630 shares at an average price of $38.05 for $0.25 million. The insider now directly holds 167,393 shares of Ionis Pharmaceuticals Inc (IONS).
